Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
David B. Solit(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Adil Daud(University of California, San Francisco), Daniel G. Coit(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Katherine S. Panageas(Mayo Clinic), Neal Rosen(Memorial Sloan Kettering Cancer Center), James S. Goydos(Rutgers, The State University of New Jersey), David Polsky(New York University), Iman Osman(New York University), F. Joseph Germino(Rutgers Cancer Institute), Jerrold B. Teitcher(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k